Trevi Therapeutics, Inc. — Director's Dealing 2021

Feb 19, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Trevi Therapeutics, Inc. (TRVI)
CIK: 0001563880
Period of Report: 2021-02-17

Reporting Person: SCIASCIA THOMAS (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-17	Stock Option (right to buy)	$3.21	A	50000	Acquired	2031-02-16	Common Stock (50000)	Direct

Footnotes

F1: This option was granted on February 17, 2021. The 50,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 17, 2022 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 17, 2025.